GET HELP NOW - email us


    Byetta Lawyer

    The drug Byetta (exenatide), manufactured by Amylin Pharmaceuticals and Bristol Myers Squibb is an injectable drug that has been prescribed to millions of Americans with Type 2 diabetes to lower blood glucose levels. Recent studies have linked Byetta, along with other drugs in the same class of medications, Januvia, Janumet and Victoza to pancreatitis and pancreatic cancer. Acute pancreatitis and pancreatic cancer are very serious conditions that can cause death. A new study by researchers at UCLA linked Byetta, along with other drugs in this incretin mimetic class of drugs to pancreatic damage that can lead to cancer, and the FDA continues to study this information.

    Cases are already filed against Amylin, Merck & Company and Novo Nordisk in Federal Court

    A multi-district case has been organized in the United States District Court for the Southern District of California for purposes of discovery. These cases were filed against Januvia makers Merck & Company, Byetta’s manufacturer, Amylin, Bristol Myers Squibb, as well as Eli Lilly, a prior pharmaceutical partner with Amylin, and Novo Nordisk, the manufacturer of Victoza. The lawsuits were recently consolidated into a multi-district litigation by the federal judicial panel, and discovery is progressing.

    Byetta was designed to help diabetics regulate blood sugar

    Byetta (exenatide) is a glucagon like peptide antagonist that impacts the GLP-1 metabolic pathway to help diabetics regulate their blood sugar and A1C. Scientific studies show that Byetta and other incretin mimentic drugs used to treat type 2 diabetes can cause both hemorrhagic and necrotizing pancreatitis. According to a 2011 study in the Journal Gastroenterology, based on a clinical study done at the University of California at Los Angeles (UCLA) people taking Byetta, Januvia, Janumet and Victoza and for type 2 diabetes are significantly more likely to develop pancreatic cancer, while people taking Januvia are also significantly more likely to develop thyroid cancer. Contact our Byetta lawsuit lawyers in Pennsylvania to discuss your case more thoroughly.

    JAMA finds people taking Incretin Mimetic Drugs are likely to be hospitalized for pancreatitis

    In addition, new research published in the Journal of the American Medical Association (JAMA) showed that patients taking incretin mimetic drugs such as Byetta are significantly more likely to develop pancreatic ailments and be hospitalized for acute pancreatitis, often a precursor to pancreatic cancer

    Although this information on development of pancreatic cancer has been available since 2011, Amylin, Merck, Bristol Myers Squibb and Novo Nordisk have been reluctant to warn the public about the increased risk for developing these devastating conditions after taking Byetta, Januvia, Janumet and Victoza. Despite these risks, the FDA recently declined to update the existing warnings on the drugs in their prescribing information.

    inner-content-img3Schedule a Consultation at Our Williamsport, Pennsylvania, Office

    If you suspect Byetta use for more than six months caused pancreatic cancer in you or a loved one, you need legal help so you can seek justice. If you or a loved one has taken Byetta, contact us today to learn about your legal rights and the potential compensation available. Call attorney Cliff Rieders, Esquire, of Rieders, Travis, Humphrey, Waters & Dohrmann, 570-323-8711, to see whether you or a loved one may be entitled to compensation from the harm caused by the drug company.

    Attorney Cliff Rieders

    Attorney Cliff RiedersCliff Rieders is a Nationally Board Certified Trial Lawyer practicing personal injury law. A large part of his practice involves multi-district litigation, including cases related to pharmaceuticals, vitamin supplements and medical devices. He is admitted in several state and federal courts, as well as the Supreme Court of the United States. Rieders is the past regional president of the Federal Bar Association and is a life member of the distinguished American Law Institute, which promulgates proposed rules adopted by many state courts. He is a past president of the Pennsylvania Association for Justice, formerly Pennsylvania Trial Lawyers Association. As a founder of the Pennsylvania Patient Safety Authority, he served on the Board for 15 years.

    Not only has Rieders held many highly esteemed, leadership positions, he authored legislation related to the Patient Safety Authority and the Mcare Act, which governs medical and hospital liability actions in Pennsylvania. He authored texts upon which both practitioners and judges rely, including Pennsylvania Malpractice Laws and Forms, and Financial Responsibility Law Issues in Pennsylvania, the latter governing auto and truck collisions in Pennsylvania. In addition, he wrote several books on the practice of law in Pennsylvania regarding wrongful death and survivor actions, insurance bad faith, legal malpractice claims and worker rights, among others. Rieders also serves as a resource to practitioners as a regular speaker for Celesq, an arm of the world’s largest legal publisher, Thomson Reuters West Publishing.

    As recognition of his wide range of contribution to his profession and of his dedication to protecting the rights of his clients, he received numerous awards, among them the George F. Douglas Amicus Curiae Award, the Milton D. Rosenberg Award, the B’nai B’rith Justice Award, and awards of recognition from the Pennsylvania Trial Lawyers. [ Attorney Bio ]

    Our Legal Team

    AttorneyClifford A. Rieders
    Partner
    Jeffrey C. Dohrmann
    AttorneyJeffrey C. Dohrmann
    Partner
    Corey J. Mowrey
    AttorneyCorey J. Mowrey
    Associate
    Attorney John Humphrey
    AttorneyJohn M. Humphrey
    Partner
    Attorney Walter
    AttorneyC. Scott Waters
    Partner
    Pamela L. Shipman
    AttorneyPamela L. Shipman
    Associate

    RECENT ARTICLES

    • COVID-19-DEATH CASE

      PA Drug Injury AttorneyTesta v. Broomall, Pa. Civil No. 21-5148-KSM (E.D. Pa. August 18, 2022) (Marston, J.)  COVID-19 death case in a nursing home.  Motion to dismiss denied.  The claim was based upon the fact that although decedent tested positive for COVID-19, she was permitted to travel out of her room to interact with other residents and to get her nails done while she was placed in isolation.  She had a “win...

    • MEDICAL MALPRACTICE-PRIVILEGE
    • DRAM SHOP ACT-PREEMPTION OF NEGLIGENCE CLAIM

    SIGN UP FOR OUR NEWSLETTER